Neurology: Volume 91, Number 19, November 6, 2018 Exam #1 - Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US

About this course

  • Released: 11/06/2018
  • Expires: 11/06/2021


USE OF NEWER DISEASE-MODIFYING THERAPIES IN PEDIATRIC MULTIPLE SCLEROSIS IN THE US

LEARNING OBJECTIVES:

Upon completion of the article by Krysko et al, the participant should be able to:

  • State the proportion of pediatric patients with demyelinating disease who were treated with at least one form of newer disease modifying therapy (DMT) prior to age 18 in this study
  • Describe the incidence of known and new side effects in pediatric patients receiving DMT in this study compared to adults receiving similar therapeutic regimens
  • Identify patient and disease-specific predictors associated with a higher likelihood of receiving a newer DMT option in patients with pediatric demyelinating disease in this study

 

CORE COMPETENCIES:

The article by Krysko et al covers the following core competency:

  • Medical Knowledge
     

AUTHOR DISCLOSURES:

Refer to Information and Author section available in the Tool Bar for each article.

 

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

AMA CREDIT DESIGNATION STATEMENT

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

James WM Owens Jr. MD, PhD receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology. Adam Kelly, MD, has served as a guest editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.

COMMERCIAL SUPPORT

This CME program receives no commercial support.

ACCME